Low thymidylate synthase expression in the primary tumor predicts favorable clinical outcome in resected gastric cancer patients treated with adjuvant tegafur

Oncology

Volumn 66, Issue 3, 2004, Pages 226-233

  Grau, Juan J ^a   Domingo Domenech, Josep ^b   Morente, Vanesa ^b   Pera, Manuel ^b   Garcia Valdecasas, Juan C ^b   Fuster, Josep ^b   Bombí, Antoni ^b   Mellado, Begoña ^b   Albanell, Joan ^b   Gascón, Pere ^b  

^a HOSPITAL CLÍNIC   (Spain)

^b NONE

Author keywords

Adjuvant chemotherapy; Gastric cancer; Mitomycin; Tegafur; Thymidylate synthase

Indexed keywords

MITOMYCIN C; MONOCLONAL ANTIBODY; TEGAFUR; THYMIDYLATE SYNTHASE;

ADULT; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURGERY; CANCER SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; DATA ANALYSIS; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFORMATION RETRIEVAL; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MEDICAL RECORD; MONOTHERAPY; PRIORITY JOURNAL; REVIEW; STOMACH CARCINOMA; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTIBODIES, MONOCLONAL; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MEDICAL RECORDS; MIDDLE AGED; MITOMYCIN; PREDICTIVE VALUE OF TESTS; RANDOMIZED CONTROLLED TRIALS; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TEGAFUR; THYMIDYLATE SYNTHASE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 3042675138     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000077999     Document Type: Review

References (29)

1. Macdonald JS, Smalley SR, Benedetti J, et al: Chemotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725-730.
2. Earle CC, Maroun JA: Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: Revisiting a meta-analysis of randomized trials. Eur J Cancer 1999;35:1059-1064.
3. Cirera L, Balil A, Batiste-Alentorn E, et al: Randomized clinical trial of adjuvant mitomycin plus tegafur in patients with resected stage III gastric cancer. J Clin Oncol 1999;17:3810-3815.
4. Grau JJ, Estapé J, Fuster J, et al: Randomized trial of adjuvant chemotherapy with mitomycin C plus ftorafur versus mitomycin alone in resected locally advanced gastric cancer. J Clin Oncol 1998;16:1036-1039.
5. Berger SH, Chung-Her J, Johnson LF, et al: Thymidylate synthase overproduction and gene amplification in fluorodeoxyuridine-resistant human cells. Mol Pharmacol 1987;28:461-467.
6. Clark JL, Berger SL, Mittelman A, et al: Thymidylate synthase gene amplification in a colon tumor resistant to fluoropyrimidine chemotherapy. Cancer Treat Rep 1987;71:261-265.
7. Leichman CG, Lenz H-J, Leichman L, et al: Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 1997;15:3223-3229.
8. Johnston PG, Lenz H-J, Leichman CG, et al: Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 1995;55:1407-1412.
9. Tsujitani S, Konishi I, Suzuki K, et al: Expression of thymidulate synthase in relation to survival and chemosensitivity in gastric cancer patients. J Exp Clin Cancer Res 2000;19:189-195.
10. Fleming ID, Cooper JS, Henson DE, Hutter RVP, Kennedy BJ, Murphy GP, O'Sullivan B, Sobin LH, Yarbro JW: AJCC: Cancer Staging Manual, ed 5. Philadelphia, Lippincott-Raven, 1997.
11. Johnston PG, Liang CM, Henry S, Chabner BA, Allegra CJ: Production and characterization of monoclonal antibodies that localize human thymidylate in the cytoplasm of human cells tissue. Cancer Res 1991;51:6668-6676.
12. Lessene JB, Rothschild N, Erikson B, et al: Cancer-associated hemolytic-uremic syndrome: Analysis of 85 cases from a national registry. J Clin Oncol 1989;7:781-789.
13. Peto R, Pike MC, Armitage P, et al: Design and analysis of randomized clinical trials requiring prolonged observations on each patient. Br J Cancer 1976;34:585-612.
14. Kaplan EL, Meier P: Nonparametric estimations from incomplete observations. J Am Stat Assoc 1958;53:457-463.
15. 2 in the log-rank test for survival data on tumor incidence data. Biometrics 1973;29:279-286.
16. Cox DR: Regression models and life-tables. J R Stat Soc 1972;34:187-220.
17. Johnston PG, Fisher ER, Rockette HE, et al: The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 1994;12:2040-2047.
18. Ishikawa Y, Kubota T, Otani Y, et al: Thymidylate synthase and dihydropyridine dehydrogenase levels in gastric cancer. Cancer Res 1999;19:5635-5640.
19. Navalgund LG, Rossano C, Muench AJ, et al: Cell cycle regulation of thymidylate synthase gene expression in cultured mouse fibroblasts. J Biol Chem 1980;255:7386-7390.
20. Kuniyasu T, Nakamura T, Tabuchi Y, Kuroda Y: Immunohistochemical evaluation of thymidylate synthase in gastric carcinoma using a new polyclonal antibody. Cancer 1998;83:1300-1306.
21. Lenz H-J, Leichman CG, Danenberg KD, et al: Thymidylate synthase mRNA level in adenocarcinoma of the stomach: A predictor for primary tumor response and overall survival. J Clin Oncol 1996;14:176-182.
22. Suda Y, Kuwashima Y, Tanaka Y, Uchida K, Akazawa S: Immunohistochemical detection of thymidylate synthase in advanced gastric cancer: A prognostic indicator in patients undergoing gastrectomy followed by adjuvant chemotherapy with 5-fluropyrimidines. Anticancer Res 1999;19:805-810.
23. Choi JH, Lim HY, Nam DK, et al: Expression of thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection. Br J Cancer 2001;84:186-192.
24. Edler D, Glimelius B, Hallström M, et al: Thymidylate synthase expression in colorectal cancer: A prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. J Clin Oncol 2002;20:1721-1728.
25. Takenoue T, Nagawa H, Matsuda K, et al: Relation between thymidylate synthase expression and survival in colon carcinoma, and determination of appropriate application of 5-fluorouracil by immunohistochemical method. Ann Surg Oncol 2000;7/3:193-198.
26. Harstrick A, Gonzales A, Schleucher N, et al: Comparison between short or long exposure to 5-fluorouracil in human gastric and colon cancer cell lines: Biochemical mechanism of resistance. Anticancer Drugs 1998;9:625-634.
27. Yeh KH, Yeh SH, Hsu CH, Wang TM, Ma IF, Cheng AL: Prolonged and enhanced suppression of thymidylate synthase by weekly 24-h infusion of high-dose 5-fluorouracil. Br J Cancer 2000;83:1510-1515.
28. Aschele C, Sobrero A, Faderan MA, Bertino JR: Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules. Cancer Res 1992;52:1855-1864.
29. Wang FS, Aschele C, Sobrero A, et al: Decreased folylpolyglutamate synthetase expression: A novel mechanism of 5-fluorouracil resistance. Cancer Res 1993;53:3677-3680.